Tuesday - March 24, 2026
FDA Approval of Icotyde Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis With a Targeted Oral Peptide
March 19, 2026
RARITAN, New Jersey, March 19 -- Johnson and Johnson Innovative Medicine issued the following news release on March 18, 2026:

* * *

FDA approval of ICOTYDE(TM) (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill

ICOT . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products